Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MPO | P05164 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 5/20 | 0.54 |
| ▸ | CA1 | P00915 | 5/20 | 0.54 |
| ▸ | CA9 | Q16790 | 5/20 | 0.54 |
| ▸ | CA2 | P00918 | 4/20 | 0.54 |
| ▸ | CA7 | P43166 | 4/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619724 | 0.85 | CES2 (0.50) | KDM4EMPOGAASMN1; SMN2HIF1A | |
| SCHEMBL14880049 | 0.80 | CA1 (0.55) | KDM4ECA12CA1CA9CA2 | |
| SCHEMBL6501339 | 0.78 | CA12 (0.58) | KDM4EGAACA12CA1CA9 | |
| SCHEMBL8424844 | 0.78 | CA1 (0.52) | KDM4EMPOGAAHIF1ACA12 | |
| SCHEMBL9314455 | 0.78 | HDAC6 (0.48) | KDM4EMPOGAASMN1; SMN2HIF1A | |
| SCHEMBL29638147 | 0.78 | HDAC1 (0.45) | KDM4EMPOGAASMN1; SMN2HIF1A | |
| SCHEMBL9313956 | 0.75 | CYP3A4 (0.52) | KDM4EMPOGAASMN1; SMN2HIF1A | |
| SCHEMBL1436240 | 0.75 | GAA (0.69) | KDM4EMPOGAASMN1; SMN2HIF1A | |
| SCHEMBL6992219 | 0.73 | CES2 (0.58) | KDM4EGAATHRBHDAC6HDAC1 | |
| Salicylhydroxamic Acid SCHEMBL21530845 | 0.73 | KDM4E (1.00) | KDM4EMPOGAASMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524941-B2 | Methods for the preparation of chemically misaminoacylated tRNA via protective groups | AMBERGEN, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20080287710-A1 | Methods for the preparation of chemically misaminoacylated tRNA via protective groups | AMBERGEN, INC. | 2008-11-20 | — | — | US | disclosed |
| EP-1472372-A4 | METHODS FOR THE PREPARATION OF CHEMICALLY MISAMINOACYLATED tRNA VIA PROTECTIVE GROUPS | AMBERGEN INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7288372-B2 | Methods for the preparation of chemically misaminoacylated tRNA via protective groups | AMBERGEN, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1165569-B1 | BORONIC ACID CONTAINING REAGENTS AND OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES INC (US) | 2005-08-10 | — | — | EP | disclosed |
| US-6870065-B2 | Bifunctional boronic compound complexing reagents and complexes | CAMBREX BIO SCIENCE ROCKLAND, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1472372-A1 | METHODS FOR THE PREPARATION OF CHEMICALLY MISAMINOACYLATED tRNA VIA PROTECTIVE GROUPS | Ambergen, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040072203-A1 | Purification of primer extension products | PROLINX, INC. | 2004-04-15 | — | — | US | disclosed |
| US-20030219780-A1 | Methods for the preparation of chemically misaminoacylated tRNA via protective groups | AMBERGEN, INC. | 2003-11-27 | — | — | US | disclosed |
| US-6630577-B2 | Useful for producing bioconjugates | PROLINX, INC. | 2003-10-07 | — | — | US | disclosed |
| EP-0915832-A1 | BORONIC COMPOUND COMPLEXING REAGENTS AND HIGHLY STABLE COMPLEXES | PROLINX, INC. (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5877297-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| US-5876938-A | Use of boron-containing polynucleotides as diagnostic agents | PROLINX, INCORPORATED (US) | 1999-03-02 | — | — | US | disclosed |
| US-5872224-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5837878-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5831045-A | Boronic acid-containing polynucleotides | PORLINX, INCORPORATED (US) | 1998-11-03 | — | — | US | disclosed |
| US-5831046-A | Boronic acid-contaning nucleic acid monomers | PROLINX, INCORPORATED (US) | 1998-11-03 | — | — | US | disclosed |
| US-5777148-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1998005672-A1 | NOVEL BORONIC ACID-CONTAINING NUCLEIC ACIDS AND THEIR USE AS DIAGNOSTIC AGENTS | PROLINX INCORPORATED (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1998005627-A1 | BORONIC COMPOUND COMPLEXING REAGENTS AND HIGHLY STABLE COMPLEXES | PROLINX, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287710-A1 | Methods for the preparation of chemically misaminoacylated tRNA via protective groups | NSUN3, TRMT1, TARBP1 | KDM4E 2377/4885MPO 2921/4885GAA 1537/4885 |
| US-20030219780-A1 | Methods for the preparation of chemically misaminoacylated tRNA via protective groups | NSUN3, TRMT1, TARBP1 | KDM4E 2377/4885MPO 2921/4885GAA 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.